Second, although we only included patients whose last attack was transverse myelitis, most patients with RRMS or AQP4 + NMOSD had experienced optic neuritis or demyelinating brain attacks earlier during their disease course, which may have affected their levels of serum biomarkers. This evidence concerns the gene AQP4 and optic neuritis.